Targeting endothelial thioredoxin-interacting protein (TXNIP) protects from metabolic disorder-related impairment of vascular function and post-ischemic revascularisation

ConclusionCollectively, these results show that targeting endothelial TXNIP in metabolic disorders is essential to maintaining endothelial function, vascular function and improving ischemia-induced revascularisation, making TXNIP a potential therapeutic target for therapy of vascular complications related to metabolic disorders.

http://link.springer.com/10.1007/s10456-019-09704-x

Source: Angiogenesis - January 2, 2020 Category: Molecular Biology Source Type: research